Lakefront Biotherapeutics American Depositary Shares
LKFT
90 hedge funds and large institutions have $793M invested in Lakefront Biotherapeutics American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 24 increasing their positions, 31 reducing their positions, and 16 closing their positions.
89% more call options, than puts
Call options by funds: $46.7M | Put options by funds: $24.8M
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
33% more capital invested
Capital invested by funds: $595M → $793M (+$198M)
8% more funds holding
Funds holding: 83 → 90 (+7)
3.08% more ownership
Funds ownership: 16.47% → 19.54% (+3.1%)
23% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 31
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$130M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$59.4M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$29.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$31.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$27.9M |
| 3 |
6CM
683 Capital Management
New York
|
-$25.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.6M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$9.25M |
LKFT Hedge Fund Activity: Q1 2022 in Review
90 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2022, worth a combined $793M — up 33% from $595M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LKFT positions and 16 closed out — a net gain of 8 holders — while 24 added to existing stakes and 31 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $130M. The largest seller was OrbiMed, cutting an estimated $31.2M.
- 90 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2022, up from 83 in Q4 2021.
- Funds reported $793M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2022, up 33% quarter-over-quarter.
- 24 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2022 and 16 closed out, a net change of +8 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2022 was Fidelity Investments, an estimated $130M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2022 was OrbiMed, an estimated $31.2M sold.
Based on aggregated 13F filings for Q1 2022.